Lexeo Therapeutics (NASDAQ:LXEO) Shares Down 3.5% – Here’s What Happened

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) shares were down 3.5% on Tuesday . The company traded as low as $9.89 and last traded at $9.91. Approximately 173,282 shares traded hands during trading, a decline of 79% from the average daily volume of 843,957 shares. The stock had previously closed at $10.27.

Analysts Set New Price Targets

A number of research analysts have weighed in on LXEO shares. Oppenheimer reissued an “outperform” rating and issued a $20.00 target price on shares of Lexeo Therapeutics in a research note on Wednesday, December 10th. Chardan Capital reaffirmed a “buy” rating and issued a $17.00 price target on shares of Lexeo Therapeutics in a report on Thursday, December 11th. Wall Street Zen raised Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 8th. HC Wainwright reaffirmed a “buy” rating on shares of Lexeo Therapeutics in a research note on Monday, November 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Lexeo Therapeutics in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Lexeo Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $19.33.

Lexeo Therapeutics Stock Down 3.7%

The business has a 50-day simple moving average of $9.46 and a 200-day simple moving average of $6.71. The company has a market cap of $721.87 million, a PE ratio of -3.66 and a beta of 1.76.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.15. As a group, equities research analysts predict that Lexeo Therapeutics, Inc. will post -3.14 EPS for the current fiscal year.

Insider Activity

In related news, insider Eric Adler sold 3,382 shares of Lexeo Therapeutics stock in a transaction that occurred on Friday, October 17th. The shares were sold at an average price of $8.94, for a total value of $30,235.08. Following the completion of the transaction, the insider owned 73,261 shares in the company, valued at approximately $654,953.34. The trade was a 4.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Tai Sandi See sold 3,888 shares of the stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $8.94, for a total transaction of $34,758.72. Following the sale, the insider owned 65,862 shares in the company, valued at approximately $588,806.28. This trade represents a 5.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 24,646 shares of company stock valued at $221,037. 5.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. CWM LLC boosted its stake in shares of Lexeo Therapeutics by 150.3% in the 2nd quarter. CWM LLC now owns 10,351 shares of the company’s stock valued at $42,000 after buying an additional 6,216 shares during the period. Ethic Inc. acquired a new stake in Lexeo Therapeutics in the second quarter valued at approximately $44,000. Cerity Partners LLC purchased a new position in Lexeo Therapeutics in the second quarter worth approximately $50,000. Intech Investment Management LLC grew its holdings in Lexeo Therapeutics by 20.7% during the 2nd quarter. Intech Investment Management LLC now owns 13,682 shares of the company’s stock worth $55,000 after acquiring an additional 2,342 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in Lexeo Therapeutics during the 2nd quarter worth approximately $60,000. 60.67% of the stock is owned by institutional investors and hedge funds.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.